Caxton Associates (New York)’s Usana Health Sciences USNA Stock Holding History

Caxton Associates (New York)’s Portfolio USNA Stock Details USNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,928	Closed	-$373K	–	657
2023 Q1	$373K	Sell	5,928 -2,159	-27%	-$129K	0.06%	312
2022 Q4	$430K	Sell	8,087 -8,034	-50%	-$435K	0.03%	268
2022 Q3	$904K	Buy	16,121 +1,962	+14%	+$130K	0.12%	138
2022 Q2	$1.02M	Buy	14,159 +11,163	+373%	+$831K	0.1%	121
2022 Q1	$238K	Hold	2,996	–	–	0.02%	408
2021 Q4	$303K	Sell	2,996 -390	-12%	-$38.9K	0.03%	409
2021 Q3	$312K	Hold	3,386	–	–	0.03%	305
2021 Q2	$347K	Hold	3,386	–	–	0.04%	266
2021 Q1	$330K	Buy	+3,386	New	+$308K	0.03%	254
2020 Q3	–	Sell	-3,742	Closed	-$275K	–	520
2020 Q2	$275K	Buy	+3,742	New	+$294K	0.02%	287
2019 Q2	–	Sell	-3,443	Closed	-$289K	–	532
2019 Q1	$289K	Buy	+3,443	New	+$359K	0.04%	262
2018 Q4	–	Sell	-2,699	Closed	-$325K	–	475
2018 Q3	$325K	Sell	2,699 -1,851	-41%	-$230K	0.02%	311
2018 Q2	$525K	Buy	+4,550	New	+$498K	0.03%	236

Other funds holding USNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Pzena Investment Management New York $30.8B AUM 11.29% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caxton Associates (New York)'s USNA Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Usana Health Sciences (USNA) in Q2 2023, closing a stake of 5,928 shares — an estimated $373K sold.

Caxton Associates (New York) first reported a position in USNA in Q2 2018 and held it in 13 quarters. The position peaked at $1.02M in Q2 2022. 169 funds tracked by Wall St. Rank hold USNA as of Q2 2023.

Caxton Associates (New York) reported no remaining Usana Health Sciences position as of Q2 2023 after selling out during the quarter.
Caxton Associates (New York) sold 5,928 Usana Health Sciences shares in Q2 2023, an estimated $373K.
Caxton Associates (New York) first reported a position in Usana Health Sciences in Q2 2018 and held it in 13 quarters.
Caxton Associates (New York)'s Usana Health Sciences position peaked at $1.02M in Q2 2022.
169 funds tracked by Wall St. Rank held Usana Health Sciences as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.